Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Download PDF Copy

Mar 17 2010

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs. the control group, and showed that mapatumumab was well tolerated in this study. HGS expects to present the results in full at an appropriate scientific meeting later in 2010.

Source Human Genome Sciences

Posted in: Drug Trial News | Medical Procedure News | Medical Condition News

Tags: Anthrax, Antibody, Apoptosis, B Cell, Cancer, Carboplatin, Cell, Chemotherapy, Coronary Heart Disease, Diabetes, Genome, Hepatitis C, Lung Cancer, Lungs, Lupus, Monoclonal Antibody, Multiple Myeloma, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Small Cell Lung Cancer, T-Cell, Type 2 Diabetes

Comments (0)

Download PDF Copy

Suggested Reading

Study unlocks genetic secrets in APOEε4 carriers that could defend against Alzheimer's

Study unlocks genetic secrets in APOEε4 carriers that could defend against Alzheimer's

Tea consumption increases bone density and reduces the risk of osteoporosis

Tea consumption increases bone density and reduces the risk of osteoporosis

Persistent COVID-19 could drive virus evolution, new study suggests

Persistent COVID-19 could drive virus evolution, new study suggests

Does IBD affect cancer risk?

Does IBD affect cancer risk?

Childhood obesity not linked to adult skin cancer risk, study says

Childhood obesity not linked to adult skin cancer risk, study says

Genetic and lifestyle factors linked to brain network aging, study reveals

Genetic and lifestyle factors linked to brain network aging, study reveals

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

Could dried fruits be the key to reducing osteoarthritis risk?

Could dried fruits be the key to reducing osteoarthritis risk?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Groundbreaking study unveils sex-specific genetic influences on blood pressure